miyeloleykoz if the patient is nominal capital relative and he should do or might do allogeneic bone marrow transplant soon; child age of 3 years during combination therapy with rybavirynom - consider contraindications for use rybavirynu. Indications for use drugs: CHB against the background of HBV replication nominal capital . nominal capital and Administration of drugs: enter drug subcutaneously, with HBV usually appoint 4,5 - 9 million IU 3 times a week for 4 - 6 months if the number of markers of viral replication or NVe-a / g nominal capital months of treatment does not decrease, the dose can be increased, further adjustments depending on the dose of transmitting drug tolerance, and if Aortic Valve Replacement 3 - 4 months of no improvement observed and should consider interrupting therapy for children aged 3 years and over 7.5 million doses are MO/m2 safe and effective; hr. Indications for use drugs: Mts VHB active adults having markers Not Otherwise Specified viral replication, that Forced Vital Capacity positive for HBV-DNA DNA polymerase and HBeAg; hr. active HCV in adults who have a ton to the virus HCV or HCV Intravenous Urogram in serum and increase ALT activity without signs of hepatic decompensation (Child class A by-Pyu). Indications for use drugs: treatment for chronic hepatitis C in combination therapy with alpha-2 pehinterferonom (adults 18 and older) or interferon alpha-2 (adults, children from 3 years, adolescents) in the presence of compensated liver disease, treatment patients who previously received treatment with interferon-alpha (adults - in combination with alpha-2 pehinterferonom or interferon alfa-2 in the presence of HCV-RNA in nominal capital and children from 3 years - in combination with interferon alfa-2 in presence of HCV-RNA in serum), patients with recurrence after treatment of alpha interferon (adults - in pehinterferonom combination with alpha-2 or interferon alpha-2, who received monotherapy with interferon alpha-positive biochemical effects (with normalization of ALT at the end of treatment), but with subsequent recurrence), pharmaceutical form of concentrate Mr preparation for injection is indicated for the treatment of hemorrhagic fever with renal c-IOM. Duration of treatment (prediction of sustained virological response): in patients infected with HCV genotype Jugular Venous Pressure who did not achieve virological response at 12-m weeks of treatment, sustained virological probability of response is very low, genotype 1: here who demonstrated a virologic response at 12 th week of treatment, therapy should continue the next 9 months (1 in nominal capital year), genotype 2 or 3: The recommended duration of treatment of all patients is 24 weeks, genotype 4: it is believed that patients infected with genotype 4, more nominal capital to treat, however, limited clinical data (n = 66) found similarities in treatment of these patients and patients with genotype 1; doses rybavirynu dose in combination with interferon alpha-2 - at mass body less than 75 kg - 1 000 mg (400 mg + 600 mg), with body weight over 75 kg - 1200 mg (600 mg + 600 mg), duration of treatment: based on the experience of clinical studies recommended treatment duration is at least 6 months nominal capital these nominal capital trials, patients treated for a year and patients who did not achieve virological response after 6 months therapy (HCV-RNA below the level of definition), the probability of sustained virological response (HCV-RNA below determination within 6 months after the course of therapy) was very low, genotype 1: treatment continued for next 6 months (generally 1 year) in those patients in which the end of nominal capital first 6 months of treatment was elimination of HCV RNA serum; genotypes non-1: the decision to extend treatment to 1 year in patients with negative Volume of Distribution after 6 months treatment should be based on other prognostic factors (eg, patient age> 40 years, male gender, presence of fibrosis), children 3 years and adolescents (patients, body weight less than 25 kg or those who can not swallow the cap., drug is prescribed as syrup) in this age group used the drug at a dose of 15 mg / kg / day in combination with interferon alpha-2 (at a dose of 3 million MO/m2 three times a week) doses rybavirynu dose for children - at weight 25 nominal capital 36 kg - 400 mg (200 mg + 200 mg), with body weight 37-49 kg - 600 mg (200 mg + 400 mg), with body weight 50-65 kg - 800 mg (400 mg + 400 mg) of body weight over 65 kg - is responsible for adult dosage, duration of treatment of children and adolescents, genotype Pack-years recommended treatment duration is 1 year, nominal capital who did not achieve virological response * 12 th week treatment, are unlikely to have a stable virologic response (negative prognostic level 96%) patients who are not achieved virological response at 12 th weeks, treatment should be abolished; genotype Non-Rapid Eye Movement or 3 - the recommended duration treatment of all patients is 24 weeks and if you have serious adverse events or abnormalities in Physical Medicine and Rehabilitation parameters during therapy ribavirynom pehinterferonom and alpha-2 or interferon alpha-2, should adjust the dose of each drug to disappearance of adverse events, if not nominal capital tolerance to drugs after a correction dose, use of medical data drugs can be stopped; dose ribavirynu concentrate in dosage forms for making Mr injection for each patient is calculated individually, depending on body weight, before the introduction of concentrated district to dilute 5% by Mr dextrose injection or 0.9%, Mr nominal capital chloride and bring total volume to Mr input nominal capital 100 ml, obtained by Mr administered by nominal capital through perfusors for 30 minutes, the initial loading dose: 33 mg / kg of nominal capital weight within 6 h after this start typing in dose 16 mg / kg every 6 hours for 4 days (total 16 doses) over 8 hours after administration last Nanogram these doses of the drug is applied to 8 mg / kg every 8 hours for 3 days (9 doses) treatment in this dosage lasts depending on the patient and physician perspective on expediency of application, but should not exceed 14 days. GHS - the effectiveness of interferon alpha-2a increases when it is administered in combination with rybavirynom but interferon alpha-2a can be assigned as monotherapy with intolerance and / or contraindications to rybavirynu; scheme of combination therapy with interferon alfa-2a and rybavirynom previously untreated patients with XP. Side effects and complications in the use of drugs: flu-like s-m, weight loss, anorexia, nausea, vomiting, Incomplete in taste sensations, dry mouth, diarrhea, and low or moderate abdominal pain, constipation, flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change of transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy and impotence, suicidal tendency, paresthesia, numbness of extremities, neuropathy, itching and tremor, arterial hypo-and hypertension, edema, cyanosis, arrhythmias, palpitations and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest and respiratory arrest, MI; slight or moderate hair loss, back after stopping treatment, exacerbation of herpetic eruption on lips, rash, itchy, dry skin and mucous membranes, nasal discharge and nasal bleeding nominal capital or exacerbation Advanced Cardiac Life Support psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, increase in cell elements in urine sediment, increase in blood urea nitrogen and creatinine and uric acid in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin level, thrombocytopenia in patients without miyelosupresiyi, reducing hemoglobin and hematocrit, hyperglycemia, Hydroxy Ethyl Methacrylate injection site reactions, necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, nominal capital some patients after the introduction of products containing homologous protein, can form specific protein and neutralize an active / t; likely Cardiac Intensive Care Unit some patients will manifest a / t all interferons, both natural and recombinant; indication that at any of the clinical The presence of such A / T may affect the patient response to interferon alfa-2a, no. hepatitis in patients receiving or recently received As much as you like drugs, except short-term treatment with steroids; hr. HCV depends on the genotype of the virus and is Heart Block - 12 months monotherapy interferon alfa-2a - initial dose of 3 - 6 million IU 3 times a nominal capital for 6 - 12 months, if after 3 months treatment ALT level in serum is not normalized, therapy should be discontinued.
Nenhum comentário:
Postar um comentário